99mTc-EDDA/HYNIC-octreotate in detection of atypical bronchial carcinoid.
Pulmonary carcinoids cause serious difficulties in imaging diagnostics in all stages of the disease. SRS holds great promise for detecting occult primary tu and metastatic lesions. (99m)Tc-EDDA/HYNIC-octreotate, a new scintigraphic agent, should significantly improve sensitivity of the diagnostics of carcinoids due to better affinity to SSR2 than (111)In-Octreoscan and the higher count rate obtained from (99m)Tc over (111)In. We present a case of a 40-year-old women operated on because of lung carcinoid tumour in 2002. The symptoms did not resolve after the operation and 5-OHIAA was still elevated. The thorax spiral CT revealed the focal lesion beneath carina. (111)In-Octreoscan and (99m)Tc-EDDA/HYNIC-octreotate SRS revealed two focal lesions in the mediastinum. (99m)Tc-EDDA/HYNIC-octreotate detected two additional lesions in the lower part of the right lung. Target/non-target count ratios of the lesions were as follows: (99m)Tc-EDDA/HYNIC-octreotate scans - 2,9, (111)In-Octreoscan- 2,1. PET-FDG examination revealed no pathology. Owing to severe bone pains and carcinoid symptoms the patient was referred for the 90Y-DOTA-octreotate treatment.


CONCLUSIONS
SRS with a new 99mTc marked somatostatin analogue - octreotate allows for a more sensitive detection of metastatic leasions in carcinoid tumours. The usefulness of 18F-FDG PET, widely used as a powerful imaging technique in clinical oncology, is limited in detection of carcinoid tumours due to the low proliferative activity.
Hubalewska-Dydejczyk
A
A
Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland. alahub@cm-uj.krakow.pl
Fröss-Baron
K
K
Gołkowski
F
F
Sowa-Staszczak
A
A
Mikołajczak
R
R
Huszno
B
B
D000328:Adult; D002276:Carcinoid Tumor / Q000000981:diagnostic imaging* / Q000628:therapy; D004492:Edetic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D006834:Hydrazines; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy; D008479:Mediastinal Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary / Q000628:therapy; D009362:Neoplasm Metastasis; D009539:Nicotinic Acids; D015609:Organotechnetium Compounds / Q000008:administration & dosage; D011859:Radiography; D019275:Radiopharmaceuticals / Q000008:administration & dosage*; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives
C120392:6-hydrazinopyridine-3-carboxylic acid; D006834:Hydrazines; D009539:Nicotinic Acids; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D013004:Somatostatin; C026058:EDDA; D004492:Edetic Acid; C081788:pentetreotide